| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_374bd30b140c412aedda14571cbbc4a7 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7023
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0034
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-006
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0043 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D237-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F13-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-04 |
| filingDate |
1998-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_20396dcf3a04bcda7250005a529c9651
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_30e550120ddec42697135ea7d2206f81
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c031a779ba749da547da4b0dfe35106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2d093e5cf3fe314117c697561c6f3e58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9a828ee05a7671969e0e79271436b5dc |
| publicationDate |
2002-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EA-002197-B1 |
| titleOfInvention |
PREPARATIONS OF THE LEFT SIZE, INTENDED FOR THE INTRODUCTION THROUGH THE MUSICAL SHELL |
| abstract |
A method is described for administering to a patient through the mucous membrane, in particular through the mucous membrane of the mouth or nose, levosimendan or a pharmaceutically acceptable salt thereof. The method includes the interaction of an intact mucous membrane with a source of levosimendan and maintaining this source in contact with the specified mucous membrane for a period of time sufficient to deliver levosimendan to the patient. Levosimendan preparations for administration through the mucous membrane are also described. Levosimendan is useful in the treatment of heart failure. |
| priorityDate |
1997-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |